Cidara Therapeutics, Inc. (CDTX), a biotechnology company, today, announced it has completed enrollment in its phase IIb NAVIGATE trial of CD388 for seasonal influenza prevention.
The study, being conducted across clinical sites in the US and UK, in healthy, unvaccinated adult subjects who are not at risk of complications from influenza, has reached the target enrollment of 5,000 subjects, the company said.
In the study, subjects are administered single doses of CD388 (150mg, 300mg, 450mg) or placebo once at the beginning of the flu season. They are then monitored throughout the rest of the influenza season to track any breakthrough cases.
CDTX is currently trading at $19.15, up 8.11%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.